614-02-8

Upstream product

• 405-39-0 N,N'-di-[(phenylmethoxy)carbonyl]-L-lysine 
• 27894-50-4 methyl (2S)-2-amino-6-{[(benzyloxy)carbonyl]amino}hexanoate hydrochloride 
• 13523-84-7 N⁶-benzyloxycarbonyl-N²-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-D-lysine methyl ester 
• 52123-30-5 N²-L-lysyl-L-lysine dihydrochloride 
• 31139-36-3 dibenzyl dicarbonate 
• 24498-31-5 (S)-methyl 2-amino-6-(benzyloxycarbonylamino)hexanoate 
• 13184-13-9 dilysine 
• 13795-24-9 benzyl 4-nitrophenyl carbonate 
• 13523-84-7 N^α,N^ε-Bis(benzyloxycarbonyl)-L-lysyl-N^ε-(benzyloxycarbonyl)-L-lysine Methyl Ester 
• 501-53-1 benzyl chloroformate 
• 1155-64-2 N₆-[(benzyloxy)carbonyl]-L-lysine 

Downstream Products

• 120207-81-0 N⁶-benzyloxycarbonyl-N²-[N⁶-benzyloxycarbonyl-N²-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-L-lysyl]-L-lysine 
• 1346119-11-6 C₆₅H₁₀₁N₇O₁₀ 
• 122701-29-5 N⁶-benzyloxycarbonyl-N²-[N⁶-benzyloxycarbonyl-N²-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-L-lysyl]-L-lysine methyl ester 

Relevant academic research and scientific papers

GLUCOSE-RESPONSIVE INSULIN CONJUGATES

Glucose-responsive insulin conjugates that contain one or more linear oligomer sugar cluster are provided. Such insulin conjugates that may display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule.

CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY

The present disclosure provides conjugates that comprise an insulin molecule conjugated via a conjugate framework to two or more separate ligands that each include a saccharide, wherein the framework, ligand, saccharide and insulin molecule optionally com

CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self- immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY

Here described are compounds of formula I: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleyl group; wherein R3 and R4 are independently selected from a group consisting of C1 to C6 alkyl, and C2 to C6 alkanol; wherein X is selected from a group consisting of -CH2-, -S-, and -O- or absent; wherein Y is selected from -(CH2)n, -S(CH2)n, -O(CH2)n-, thiophene, -SO2(CH2)n-, and ester, wherein n = 1 -4; wherein a = 1 -4; wherein b=l -4; wherein c=l-4; and wherein Z is a counterion; and compounds consisting of the structure (targeting molecule)m-linker-(targeting molecule)n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including one or both of these compounds which are useful for the delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.

Synthesis and transfection efficiency of cationic oligopeptide lipids: Role of linker

In the design of new cationic lipids for gene transfection, the chemistry of linkers is widely investigated from the viewpoint of biodegradation and less from their contribution to the biophysical properties. We synthesized two dodecyl lipids with glutami